Acute Coronary Syndrome Market Report 2026

Acute Coronary Syndrome Market Overview

• Acute Coronary Syndrome market size has reached to $10.43 billion in 2025 • Expected to grow to $14.51 billion in 2030 at a compound annual growth rate (CAGR) of 7% • Growth Driver: Increasing Healthcare Expenditures Fuel Development in Coronary Syndrome Care • Market Trend: Innovative Drug Development Fuels Advancements In Acute Coronary Syndrome Treatment • North America was the largest region in 2025.

What Is Covered Under Acute Coronary Syndrome Market?

Acute coronary syndrome (ACS) refers to a range of clinical manifestations caused by abrupt, decreased blood flow to the heart. Symptoms of ACS include chest pain or discomfort (angina), shortness of breath, dizziness and other signs of heart-related distress. The treatment of acute coronary syndrome (ACS) is aimed at promptly relieving symptoms, minimizing heart damage and preventing further complications. The main types of acute coronary syndrome are non-st-elevation myocardial infarction, st-elevation myocardial infarction and unstable angina. Non-st-elevation myocardial infarction (NSTEMI) refers to a form of heart attack where one or more coronary arteries are partially or completely blocked, reducing blood supply to the heart muscle. The various treatment includes medications, statins, beta-blockers, ace inhibitors, anticoagulants and others for diagnosis includes stress tests, blood tests, imaging and others. The various route of administration includes oral and parenteral. These are used by various end-users such as hospitals, specialty clinics and others.

What Is The Acute Coronary Syndrome Market Growth Forecast?

The acute coronary syndrome market size is expected to see strong growth in the next few years. It will grow to $14.51 billion in 2030 at a compound annual growth rate (CAGR) of 7.0%. The growth in the forecast period can be attributed to development of novel anticoagulants and statins, increasing adoption of minimally invasive cardiac procedures, expansion of specialty clinics, rising government initiatives for heart disease prevention, technological advancements in imaging and stress testing. Major trends in the forecast period include rising adoption of early diagnostic techniques for acs, increased use of percutaneous coronary intervention (pci), growing awareness of acs risk factors and prevention, expansion of hospital cardiac care units, advancements in oral and parenteral acs treatments.

Global Acute Coronary Syndrome Market Segmentation

1) By Type: Non-St-Elevation Myocardial Infarction, St-Elevation Myocardial Infarction, Unstable Angina 2) By Treatment: Statins, Beta blockers, ACE inhibitors, Anticoagulants, Other Treatment 3) By Diagnosis: Stress Test, Blood Tests, Imaging, Other Diagnosis 4) By Route Of Administration: Oral, Parenteral 5) By End-User: Hospitals, Specialty clinics, Other End User Subsegments: 1) By Non-ST-Elevation Myocardial Infarction: Medical Management, Percutaneous Coronary Intervention (PCI), Coronary Artery Bypass Grafting (CABG) 2) By ST-Elevation Myocardial Infarction: Medical Management, Percutaneous Coronary Intervention (PCI), Coronary Artery Bypass Grafting (CABG) 3) By Unstable Angina: Medical Management, Percutaneous Coronary Intervention (PCI), Coronary Artery Bypass Grafting (CABG)

What Is The Driver Of The Acute Coronary Syndrome Market?

Increasing healthcare expenditures are anticipated to propel the growth of the acute coronary syndrome market. Healthcare expenditures refer to the total amount spent on healthcare-related services, products, and activities within a specified period, typically on an individual, community, national, or global level. Increasing healthcare expenditures are driven by factors such as the rising prevalence of chronic diseases, an aging population, advancements in medical technology, and growing demand for more advanced treatments and healthcare services. Increasing healthcare expenditures fuel growth in the coronary syndrome sector by enabling the development of better diagnostic technologies, advanced therapies, and comprehensive treatment options, catering to the growing demand for cardiovascular care. For instance, in May 2023, the Office for National Statistics, a UK-based statistics authority, in 2023, healthcare expenditure in the UK was approximately $362.08 billion (£292 billion), reflecting a nominal increase of 5.6%. Additionally, long-term health and social care expenditure rose by 2.8% in real terms in 2022. Therefore, increasing healthcare expenditure will drive the growth of the acute coronary syndrome industry going forward.

Key Players In The Global Acute Coronary Syndrome Market

Major companies operating in the acute coronary syndrome market are Pfizer Inc., Johnson and Johnson Limited, Siemens AG, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi-Aventis LLC., Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., AstraZeneca PLC, Abbott Laboratories, Medtronic Plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Co Ltd., Stryker Corporation, GE Healthcare Inc., Boehringer Ingelheim International GmbH, Boston Scientific Corporation, Daiichi Sankyo Company Limited, Terumo Corp., BioMérieux SA, Beckman Coulter Inc., Quidel Corporation, Bio-Rad Laboratories Inc., Biotronik Inc., Randox Laboratories Limited, Nihon Kohden Corporation, Trinity Biotech plc

Global Acute Coronary Syndrome Market Trends and Insights

Major companies operating in the acute coronary syndrome market are developing innovative drugs to treat acute coronary syndrome and sustain their position in the market. The advancements in drug development can increase the efficiency of ACS treatment, reducing the time and resources required for each patient. For instance, in June 2023, AGEPHA Pharma USA LLC, a US-based pharmaceutical company, launched Lodoco, which was approved by the Food and Drug Administration (FDA), a US-based government agency. This is the first anti-inflammatory atheroprotective cardiovascular treatment that reduces the risk of heart stroke, coronary revascularization, myocardial infarction (MI) and cardiovascular death in adult patients with cardiovascular diseases, including acute coronary syndrome.

What Are Latest Mergers And Acquisitions In The Acute Coronary Syndrome Market?

In May 2023, Avertix Medical Inc., a US-based company that develops implantable patient alerting systems for acute coronary syndrome (ACS), merged with BIOS Acquisition Corporation for approximately $195 million. With this merger agreement, Avertix aims to expand its portfolio commercially and continue improving and developing its innovative product, equipping patients and healthcare providers with tools. BIOS Acquisition Corporation is a US-based incorporated blank check company.

Regional Outlook

North America was the largest region in the acute coronary syndrome market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Acute Coronary Syndrome Market?

The acute coronary syndrome market consists of revenues earned by entities by providing various diagnoses through cardiac enzyme tests, blood tests and echocardiograms. The market value includes the value of related goods sold by the service provider or included within the service offering. The acute coronary syndrome market also consists of sales of percutaneous coronary intervention (PCI) drugs and angiotensin-converting enzyme (ACE) inhibitors. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Acute Coronary Syndrome Market Report 2026?

The acute coronary syndrome market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the acute coronary syndrome industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.